for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-JCR Pharmaceuticals to initiate development of JR-162

Feb 23 (Reuters) - JCR Pharmaceuticals Co Ltd :

* Says it plans to initiate development of a new drug candidate, JR-162

* Says JR-162 is a blood-brain barrier (BBB)-penetrating acid alpha-glucosidase (GAA) for treating Pompe disease which uses J-Brain Cargo, JCR’s BBB penetration technology

Source text in Japanese: goo.gl/Pf2eYc

Further company coverage: (Beijing Headline News)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up